Phenylephrine

Zhao, Dr Jing, Dept of Anaesthesiology, Peking Union Medical College Hospital, #1 Shuai Fu Yuan, Wang Fu Jing, Beijing 100730, Peoples Republic of China. Tel: + 86 10 652 Email: zhaojing pumch.ac.cn or zhaojing hotmail . Home Tel: + 86 10 652 & fax Publications Zorab, Dr John S M, Holmray Cottage, Park Street, Iron Acton, Bristol BS37 9UJ, United Kingdom. Tel: + 44 1454 228757; Fax: + 44 1454 228295; Email: JZorab compuserve . Past President 1988-1992.

CLINICAL PHARMACOLOGY Carbetapentane tannate is a centrally-acting cough suppressant that increases the threshold of the cough center in the brain to incoming stimuli thereby decreasing cough frequency. phenylephrine hydrochloride, a sympathomimetic amine, acts directly on -adrenergic receptors in the mucosa of the respiratory tract to produce vasoconstriction that increases peripheral resistance, resulting in an increase in both systolic and diastolic blood pressure. Accompanying the pressor response is a marked reflex bradycardia due to increased vagal activity. It produces vasoconstriction that lasts longer than that produced by ephedrine and epinephrine, and in therapeutic doses, produces little or no central nervous system CNS ; stimulation. Phenylephrine has reduced bioavailability from the gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver. INDICATIONS AND USAGE Carbetapentane Tannate 30 mg Phenylephrine Tannate 25 mg is indicated for the symptomatic relief of cough, coryza, and nasal congestion associated with the common cold, bronchial asthma, acute and chronic bronchitis and other upper respiratory tract conditions. Appropriate therapy should be provided for the primary disease. CONTRAINDICATIONS Carbetapentane Tannate 30 mg Phenylephrine Tannate 25 mg is contraindicated for newborns, nursing mothers, and patients who are sensitive to any of the ingredients or related compounds. WARNINGS Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma, or prostatic hypertrophy. Do not use in patients taking monoamine oxidase MAO ; inhibitors, or for 14 days after stopping treatment with an MAOI. Do not exceed recommended dosage. PRECAUTIONS General Information for patients: Caution patients against drinking alcoholic beverages or engaging in potentially hazardous activities requiring alertness, such as driving a car or operating machinery, while using this product. Patients should be warned not to use this product if they are now taking a prescription monoamine oxidase inhibitor MAOI ; certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease ; , or for 2 weeks after stopping the MAOI drug. If patients are uncertain whether a.

Dures in monographs for preparations are also written in full even within the same part, except in the monographs for preparations having a corresponding monograph of their principal material substances. 15. The following articles were deleted from O cial Monograph Part I Santonin Tablets.
Received a total of 293 appropriate therapies. Of the 9 patients with previous cardiac arrest or ventricular tachycardia, 4 received appropriate therapies. In the remaining 8 patients, with implantable cardioverter-defibrillators for primary prevention, 3 received appropriate therapies. Family history of sudden death was associated with a positive predictive value of 25% for appropriate therapies, 40% for syncope and 50% for non-sustained ventricular tachycardia. The presence of any two risk factors was associated with a positive predictive value of 33% and the presence of three factors with 100%. CONCLUSION: In this group of patients, considered to be at high risk for sudden cardiac death, a considerable percentage had ventricular tachycardias that were correctly identified and treated by the implantable cardioverter-defibrillator. The percentage of patients with appropriate therapies was slightly higher in the group who had a cardioverter-defibrillator for secondary prevention of sudden death aborted sudden death or sustained ventricular tachycardia ; . In patients with an implantable cardioverter-defibrillator for primary prevention, non-sustained ventricular tachycardia was the risk factor with the highest predictive value. An association of risk factors was also predictive of arrhythmic events. 6-66. Vijayaraghavan K, Santora L, Kahn J, Abbott N, Torelli J, Vardi G. New graduated pressure regimen for external counterpulsation reduces mortality and improves outcomes in congestive heart failure: a report from the cardiomedics external counterpulsation patient registry. Congest Heart Fail. 2005 May-2005 Jun 30; 11 3 ; : 147-52. COMPANION; MADIT II. External counterpulsation ECP ; has been shown to increase exercise tolerance and reduce angina episodes, Canadian Cardiovascular Society Functional CCSF ; class, anginal medication usage, and hospitalizations in refractive CCSF class III and IV stable angina. However, the high pressures and resulting 1.5: 1-2: 1 peak diastolic to peak systolic pressure D S ; ratios shown to be optimal in the treatment of angina can cause excessive preload and adverse effects in congestive heart failure CHF ; patients, particularly those with left ventricular ejection fractions 40%. Data were retrospectively analyzed from the Cardiomedics ECP Registry on 127 New York Heart Association NYHA ; class II-IV CHF patients 79.6% men; average age + - SD, 68.2 + -15.6 years ; , with a comorbidity of CCSF class III-IV refractive angina, who were serially treated with 35 hours of ECP 1 h d, 5 for 7 weeks ; at unconventionally low pressures and D S ratios under a new graduated pressure regimen. The pressures and D S ratios were gradually increased in stages over the 7week ECP regimen. The patients were divided into three groups based on the pressures applied and the resulting average D S ratios Low, Mid, and High ; . In the Low D S ratio group average D S ratio 0.7: 1 ; , all-cause mortality in the year following ECP treatment was only 1.85% one of 54 patients ; , whereas over the same time period in the Mid D S ratio group average D S ratio 1.08: 1 ; , all-cause mortality was 7.69% three of 39 patients ; and in the High D S ratio group average D S ratio 1.32: 1 ; , all-cause mortality was 8.82% three of 34 patients ; . For the Low, Mid, and High D S ratio groups, respectively: 1 ; average left ventricular ejection fractions increased 23.0%, 20.1%, and 17.5%; 2 ; NYHA class declined 36.6%, 29.6%, and 29.6%; and 3 ; all-cause hospitalizations, including terminal admissions, were reduced 85.7%, 82.6%, and 57.1% in the year following ECP therapy from the prior year. There were no adverse effects or withdrawals from the ECP therapy and no significant difference in sex-based outcomes. Consequently, ECP applied at low pressures and average D S ratios of 0.7: 1 under the new graduated pressure regimen is safe and effective in the treatment of CHF and produces a significant reduction in mortality, compared with the 8.5% annualized mortality of the Multicenter Automatic Defibrillator Implantation Trial II MADIT II ; N 1232 ; of NYHA class II-III CHF and the 12.2% annual mortality of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure COMPANION ; study N 595 ; of NYHA class III-IV CHF. Lower pressures improve patient comfort and may encourage more CHF patients to seek treatment. The reduction in hospitalizations should significantly reduce the cost of treating CHF. 6-67. Virk IS, Ip R. Frontiers in congestive heart failure: amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. Congest Heart Fail. 2005 May-2005 Jun 30; 11 3 ; : 158-61. 6-68. Virk IS, Ip R. Frontiers in congestive heart failure: prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. Congest Heart Fail. 2005 May-2005 Jun 30; 11 3 ; : 157-8. DINAMIT, SCD-Heft. 6-69. Wilkoff B. ICDs: dealing with less than perfect. J Cardiovasc Electrophysiol. 2005; 16 7 ; : 796-7. Guidant; Medtronic; St Jude Medical. 6-70. Winslow R, Mehta D, Fuster V. Sudden cardiac death: mechanisms, therapies and challenges. Nature Clinical Practive Cardiovascular Medicine. 2005; 2: 352-60. AMIOVIRT; AVID; CABG Patch; CASH, CAT; DEFINITE; DINAMIT; MADIT I & II; MUSTT; SCD-Heft. FIG. 1. Analysis by capillary electrophoresis. The following samples were analyzed: a, standard oligosaccharides; b, a sample that was recovered from the keratanase II-digest solution of KS by ethanol fractionation; and c, purified L4.
The present study showed that CDK4 and cyclin D1 are involved in the signaling pathway leading to apoptosis in neurons of the CNS after KA injection in vivo. Although growing evidence suggests a relationship between CDK4 and cyclin D1 and neuronal cell death, the question of whether they are essential for induction of apoptosis or are expressed to protect cells from apoptosis has yet to be clarified, although the former possibility has been strongly suggested. Upregulation of CDK4 and cyclin D1 in neurons is evident at the level of both mRNA and protein in the course of neuronal apoptosis. Although the CDK4 protein, the original function of which is unknown, is present in the cytoplasm of normal rat neurons, it is possible that newly synthesized CDK4 and cyclin D1 may be responsible for induction of apoptosis. The possible relationship between cyclin D1 and neuronal apoptosis was first described in cultured neurons, and later it was shown that cyclin D1 expression was also upregulated in ischemia- and excitotoxin-induced neuronal cell death in vivo. There may exist a common mechanism in apoptosis induction regardless of the agents. Timsit et al. 1999 ; reported the cytoplasmic and nuclear localization of cyclin D1 in hippocampal neurons after ischemia, which closely resembles our observations and phenylpropanolamine.

Flexibility in fluid and pressor management is essential for maintaining organ perfusion and blood pressure. Consequently, extreme caution should be used in treating patients with fixed requirements for large volumes of fluid e.g., patients with hypercalcemia ; . Administration of IV fluids, either colloids or crystalloids is recommended for treatment of hypovolemia. IV fluids are usually given when the central venous pressure CVP ; is below 3 to 4 H2O. Correction of hypovolemia may require large volumes of IV fluids but caution is required because unrestrained fluid administration may exacerbate problems associated with edema formation or effusions. With extravascular fluid accumulation, edema is common and ascites, pleural or pericardial effusions may develop. Management of these events depends on a careful balancing of the effects of fluid shifts so that neither the consequences of hypovolemia e.g., impaired organ perfusion ; nor the consequences of fluid accumulations e.g., pulmonary edema ; exceeds the patient's tolerance. Clinical experience has shown that early administration of dopamine 1 to 5 min ; to patients manifesting capillary leak syndrome, before the onset of hypotension, can help to maintain organ perfusion particularly to the kidney and thus preserve urine output. Weight and urine output should be carefully monitored. If organ perfusion and blood pressure are not sustained by dopamine therapy, clinical investigators have increased the dose of dopamine to 6 to min or have added phenylephrine hydrochloride 1 to 5 min ; to low dose dopamine. Prolonged use of pressors, either in combination or as individual agents, at relatively high doses, may be associated with cardiac rhythm disturbances. If there has been excessive weight gain or edema formation, particularly if associated with shortness of breath from pulmonary congestion, use of diuretics, once blood pressure has normalized, has been shown to hasten recovery. NOTE: Prior to the use of any product mentioned, the physician should refer to the Product Monograph for the respective product. PROLEUKIN treatment should be withheld for failure to maintain organ perfusion, as demonstrated by altered mental status, reduced urine output, a fall in the systolic blood pressure below 90 mm Hg onset of cardiac arrhythmias See "DOSAGE AND ADMINISTRATION" section, "Dose Modification" subsection ; . Recovery from CLS begins soon after cessation of PROLEUKIN therapy. Usually, within a few hours, the blood pressure rises, organ perfusion is restored and reabsorption of extravasated fluid and protein begins. Oxygen is given to the patient if pulmonary function monitoring confirms that PaO2 is decreased. PROLEUKIN administration may cause anemia and or thrombocytopenia. Packed red blood cell transfusions have been given both for relief of anemia and to insure maximal oxygen carrying capacity. Platelet transfusions have been given to resolve absolute thrombocytopenia and to reduce the risk of GI bleeding. In addition, leukopenia and neutropenia are observed. PROLEUKIN administration results in fever, chills, rigors, pruritus, and gastrointestinal side effects in most patients treated at recommended doses. These side effects have been aggressively managed as described in the "ADVERSE REACTIONS" section. Kidney and liver function are impaired during PROLEUKIN treatment. Use of concomitant nephrotoxic or hepatotoxic medications may further increase toxicity to the kidney or liver. 6. 4 the method of claim 34 wherein: the antitussive analgesic opioid or opiate is hydrocodone or a pharmaceutically acceptable salt thereof and is present in the composition administered in a weight range from about 5 mg to about 15 mg; thedecongestant is phenylephrine or a pharmaceutically acceptable salt thereof and is present in the composition administered in a weight range from about 1 mg to about 20 mg; and the diphenhydramine or a pharmaceutically acceptable salt thereof is presentin the composition administered in a weight range from about 3 mg to about 100 mg and pima. 0.45 ; , combined CABG and valvular replacement, patients requiring inotropic or mechanical support prior to surgery. Patients with a history of alcohol or drug abuse, clinically significant hepatic, renal or psychiatric diseases or known allergy to either study drug were also excluded. Patients were randomized in blocks of four if they successfully weaned from cardiopulmonary bypass CPB ; with a cardiac index 2.0 L-min -m"2. Postoperative exclusion criteria were: the presence of cardiac index 2.0 L m i with adequate filling pressure and requiring inotropic support or excessive bleeding 300 mL-hr"1 ; for two consecutive hours during the period of study. All patients received a standard premedication consisting of 2 mg lorazepam j and 0.15 mgkg" 1 morphine im given 90 and 30 min respectively before the procedure. All usual cardiac medications required by the patient's underlying condition were also continued. Following preoxygenation, anaesthesia was induced with 1-2 ugkg" 1 sufentanil and supplemented with isoflurane. A continuous sufentanil infusion at 0.5 ugkg- hr" 1 was initiated after induction and maintained until onset of CPB. Afterward, the sufentanil infusion was decreased to 0.25 ug-kg -hr"1 until the end of surgery. Cardiopulmonary bypass was done under mild hypothermia 32-34C ; with a membrane oxygenator. Cold blood cardioplegia was used to arrest the heart. All patients were rewarmed till bladder temperature returned to 36C. During CPB, 100 ugkg- min" 1 propofol was substituted for isoflurane. Before and after CPB, isoflurane was titrated as required to keep systolic blood pressure and heart rate within 20% of baseline ward measurements average of three to five ward measurements ; . Systolic blood pressure 120% of baseline or 160 mmHg, if not responsive to deepening with isoflurane, was treated with nitroglycerine iv. Ischaemia was treated with nitroglycerine iv in the absence of any haemodynamic change. Systolic blood pressure 80% of baseline or 90 mmHg was corrected using iv fluids, decreasing isoflurane concentration and or decreasing the sufentanil infusion and, if necessary, small boluses of ephedrine or phenylephrine were used. Intravenous metoprolol was used to maintain heart rate + 20% of baseline or 100 bpm throughout the operative period. Sinus bradycardia heart rate 50 bpm ; was treated with glycopyrrolate. Electrocardiographic episodes of ischaemia were defined as: 1 ; horizontal or downsloping ST segment depression from baseline of 1 mm lasting at least one minute and separated from other episodes by 1 min; 2 ; ST segment elevation from baseline 2 mm measured at the J point lasting at least one minute and separated from other episodes by 1 min. Neuromuscular blockade was achieved with 0.1 mgkg" 1 pancuronium at induction and prior to CPB. Muscle relaxation. Do it for yourself. Do it for your children and pindolol.

Endogenously expressed in cultured rat vascular smooth muscle cells Kai et al., 1996 ; . Studies on beta-2 adrenoceptor-induced down-regulation of Gs alpha subunits have demonstrated that the loss of Gs may quantitatively depend on the expression density of the receptor coupled to this G protein Adie and Milligan, 1994 ; . This may explain the divergent results between the present study with natively expressed receptor and those with high densities of transfected receptors. Additionally, alterations of Gq 11 expression on extended agonist exposure may depend on cell type under investigation and or the degree of effectiveness with which the receptor couples to its effector mechanisms. MDCK cell alpha1-adrenoceptors not only couple to phospholipase C activation but also can activate phospholipase A2 to enhance arachidonic acid release Xing and Insel, 1996 ; . This results in the formation of prostaglandins, which might then act on prostanoid receptors to cause heterologous downregulation of alpha-1B adrenoceptors. To investigate this possibility, experiments were performed in the presence of the cyclooxygenase inhibitor indomethacin. Because indomethacin did not affect the density of MDCK cell alpha1Badrenoceptors or the ability of phenylephrine to cause their down-regulation, formation of cyclooxygenase-derived arachidonic acid metabolites does not appear to contribute to agonist-induced alpha-1B adrenoceptor down-regulation. This hypothesis is further supported by our previous observation that alpha-1B adrenoceptor-stimulated arachidonic acid release is PKC mediated Xing and Insel, 1996 ; , whereas phenylephrine-induced alpha1B-adrenoceptor down-regulation is not present study ; . The possibility that PKC may be involved in alpha-1B adrenoceptor down-regulation was indicated by several pieces of evidence. First, stimulation of MDCK alpha-1B. On the other hand, the response to phenylephrine in reserpine-untreated artery was selectively inhibited by the same concentration of kmd-3213, but not by bmy 737 prazosin, a subtype-nonselective antagonist, blocked the responses to phenylephrine with the same potency, regardless of reserpine treatment and pitocin. Scientific Name Common Names Scientific Name Common Names Ceanothus 'Bonny Doon'. Ceanothus 'Centennial'. Ceanothus 'Concha'. Ceanothus 'Dark Star'. Ceanothus 'Frosty Blue'. Ceanothus 'Gentian Plume'. Ceanothus 'Joyce Coulter'. Creeping Mountain Lilac Ceanothus 'Marie Simon'. Ceanothus 'Montlake'. Ceanothus 'Ray Hartman'. Ceanothus 'Silver Surprise'. Ceanothus 'Spring Valley'. Ceanothus arboreus.Feltleaf Ceanothus Ceanothus arboreus 'Clifford Schmidt'. Ceanothus arboreus 'Owlswood Blue'. Ceanothus cuneatus. buckbrush, buck brush, Wedgeleaf ceanothus Ceanothus divergens ssp. confusus. Ceanothus foliosus. wavyleaf ceanothus, wavy-leaved ceanothus Ceanothus foliosus var. medius.wavyleaf buckbrush Ceanothus foliosus var. vineatus.Vine Hill ceanothus Ceanothus gloriosus. Point Reyes ceanothus Ceanothus gloriosus 'Anchor Bay'. Ceanothus gloriosus hybrid. Ceanothus gloriosus var. porrectus. Mount Vision Ceanothus, Inverness ceanothus, Point Reyes Creeper Ceanothus griseus 'Kurt Zadnik'. Ceanothus griseus 'Louis Edmunds'Carmel Mountain Lilac Ceanothus griseus var. horizontalis 'Diamond Heights'. Ceanothus griseus var. horizontalis 'Hurricane Point'. Ceanothus griseus var. horizontalis 'Yankee Point'. Ceanothus hearstiorum.Hearst Ranch buckbrush Ceanothus hearstiorum 'King Sip'. Ceanothus hybrid of x vanrensselaeri. Ceanothus impressus.Santa Barbara ceanothus Ceanothus impressus 'Vandenberg'.Santa Barbara Ceanothus Ceanothus impressus var. nipomensis.Santa Barbara ceanothus, Nipomo Mesa ceanothus Ceanothus incanus. coast whitethorn Ceanothus incanus 'Owen Pearce'. Ceanothus jepsonii. Muskbrush Ceanothus maritima. Ceanothus maritimus.maritime ceanothus Ceanothus maritimus 'Pt. Sierra'. Ceanothus megacarpus.bigpod ceanothus Ceanothus oliganthus var. orcuttii.San Diego hairy ceanothus Ceanothus papillosus var. roweanus 'Julia Phelps'. Ceanothus parryi. Parry ceanothus Ceanothus purpureusNapa ceanothus, hollyleaf ceanothus, holly-leaf ceanothus Ceanothus ramulosus.buckbrush, buck brush Ceanothus rigidus.Monterey ceanothus Ceanothus rigidus 'Snowball'. Ceanothus sp.ceanothus Ceanothus sp. hybrid. Ceanothus spinosus. greenbark ceanothus, redheart Ceanothus thrysiflorus.Blue Brush Ceanothus thrysiflorus var. repens. Ceanothus thyrsiflorus. Blue Blossom Ceanothus thyrsiflorus 'Millerton Point'. Ceanothus thyrsiflorus 'Skylark'. Ceanothus thyrsiflorus 'Snow Flurry'. White Flowered Mountain Lilac Ceanothus thyrsiflorus var. repens. creeping blueblossom Ceanothus velutinus var. laevigatus.blueblossom, blue blossom ceanothus, Blue Blossom Ceanothus x hybrid. Ceanothus x vanrensselaeri. Lake Merced Ceanothus Colletia paradoxa. Anchor Plant Colletia ulicina.Crucero, yaqui, yaquil, junco minero, cunco, chaqui Phylica buxifolia. Phylica plumosa. Phylica pubescens.featherhead Eng. veerkoppie Afr. ; Phylica sp. Pomaderris apetala. Tainui, Dogwood, Native Hazel, Hazel Pomaderris Pomaderris rugosa. Rhamnus alaternus.Italian Buckthorn Rhamnus alaternus 'Albovariegatus'.

First Nations' Values The scent of the white-flowered rhododendron was valued by the Nlaka'pmx. Several Southern Interior natives ate the berries of velvet-leaved blueberry, oval-leaved blueberry, and Sitka mountain ash. Sitka mountain ash bark was used to cure coughs, flu, and fever, while the wood was sometimes used by the Carrier to make sidesticks for snowshoes. Provision of Unique Food Habitat This complex provides valuable habitat for animals using the ESSF year-round or during the snow-free season. Although poisonous to most domestic and wild animals, rhododendron has forage value to grouse. The fruits of oval-leaved blueberry and black huckleberry are a valued food source for bears, humans, small mammals, and several bird species. Foliage and twigs of these shrubs are also important for winter browsing by deer and mountain goat. Wildlife species graze the subalpine herbs of this complex. Protection The susceptibility of falsebox to Armillaria root disease makes it a useful site indicator of the pathogen's incidence. Bioregulation White-flowered rhododendron may impede conifer performance through allelopathy and posture. This field contains the item's brand or generic name, strength volume, dosage form, package size, package description, and in parentheses, the formulary code.
Demia, or osteoporosis where the NNT is commonly between 15-25, the efficacy of Metformin appears dramatic. Moreover, these studies likely underestimated the true benefit of Metformin, since most were short-term 3-6 months ; , and Metformin treatment may require several months to achieve a full effect. It is noteworthy that the majority of studies of Metformin in PCOS did not screen women for the presence of insulin resistance or use insulin resistance as an inclusion criterion. Moreover, studies involving lean women with PCOS have reported equally positive findings. No clear predictors of a positive response to Metformin have been identified, and even lean women with seemingly normal indices of insulin action respond to treatment with Metformin. Given the demonstrated efficacy of Metformin in PCOS, the lack of confirmed predictors of positive response, and the limited risk of toxicity, a strong case can be made for an empiric trial of Metformin in all women with PCOS pursuing pregnancy. Nonetheless, several questions remain. Is Metformin monotherapy superior to clomiphene citrate in the induction of ovulation? Should Metformin be added to clomiphene immediately, or only after demonstrated failure of 16 NIH ; trial, currently being conducted by the Reproductive Medicine Network RMN ; will soon answer many of these queries. The goal of the trial is to determine the optimal pharmacologic therapy for initial induction of ovulation in women with PCOS who are seeking pregnancy. Eligible women are randomized to one of three treatment arms Metformin alone, clomiphene alone, or Metformin plus clomiphene ; , and the primary outcome measure is a live birth. Approximately 450 women have entered the trial thus far, and a total of 678 women will be studied. More information on the trial and participating sites can be found at : rmn.dcri.duke and pram.